On December 3, the China Association for Science and Technology issued the list of the 2018 model academician and expert workstations. The academician expert workstation of Wanbangde Pharmaceutical Group Co., Ltd. in our city was successfully selected, becoming the first in our city and the second in Taizhou. National model Academician expert workstation. Wanbangde Pharmaceutical Group will therefore receive 500,000 yuan of municipal talent funding awards.

In July 2002, Wanbangde Group acquired Wenling Pharmaceutical Factory, a former state-owned enterprise with a history of more than 30 years, and restructured it into Wanbangde Pharmaceutical. After more than ten years of development, Wanbangde Pharmaceutical has developed into a high-tech group enterprise specializing in the research and development, production and sales of modern traditional Chinese medicine, chemical raw materials and their preparations. The company currently has 190 drug production approval numbers, involving 18 dosage forms.

In November 2015, the academician and expert workstation of Wanbangde Pharmaceutical Group Co., Ltd. was awarded and established, becoming the fourth academician and expert workstation in our city. Tang Xican, an academician of the Chinese Academy of Engineering, a doctoral supervisor, and a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, led the station to carry out technical research on the raw materials and preparations of the anti-senile dementia drug Huperzine A. In May 2017, it was recognized as a provincial academician workstation.

Tang Xican has been engaged in the discovery of active ingredients in Chinese herbal medicines that act on the nervous system and their mechanism of action for more than 50 years. In 2001, he was elected as an academician of the Chinese Academy of Engineering. It has made important contributions to the research and development of new drugs for the treatment of neurological diseases in my country, especially Alzheimer's disease. In cooperation with phytochemists, the active ingredients such as galantamine and huperzine A have been successfully developed for the treatment of senile dementia, myasthenia gravis, chronic pain, etc.; Huperzine A was first reported to be highly effective and selective in inhibiting acetylcholinester. It is the first to report the multi-target neuroprotective effects of huperzine A, such as anti-oxidation and improvement of mitochondrial dysfunction. The research team led by him has so far published more than 200 research papers in famous international and domestic academic journals, of which 68 papers on the Huperzine A series have been published in core academic journals at home and abroad. The research results have won 3 domestic invention patents and 4 international patents.

After the establishment of the academician expert workstation, Wanbangde Pharmaceutical signed a cooperation agreement with the academician expert team of Tang Xican, which clarified the rights and obligations of both parties, and stipulated the results distribution rules to ensure the smooth progress of the cooperation between the enterprise and the academician expert team.

The academician and expert workstation is located in the Wanbangde Pharmaceutical Technology Center. The company has equipped 13 full-time technical R&D personnel and 1 workstation management personnel for the academician workstation. It has a 40-square-meter academician and expert office, more than 2,000 square meters of experimental site, and is equipped with chemical synthesis experiments. Laboratory and pilot plant, preparation laboratory, analysis center and other facilities are equipped with R&D instruments and equipment worth more than 20 million yuan.

Under the leadership of Tang Xican, the innovation team and supporting team carried out joint research on the pharmacological and pharmacological effects of synthetic Huperzine A raw material and Huperzine A intramuscular injection, and completed the synthesis of Huperzine A raw material and Huperzine A intramuscular injection. The key technology of pharmacological and pharmacodynamic research provides the relevant basis for the evaluation of Huperzine A injection and solves the key technology. Among them, the pharmacological efficacy study of Huperzine A raw material and Huperzine A intramuscular injection obtained the first domestic production approval for original research Huperzine A injection on July 31 this year; National invention patent, and obtained the clinical approval from the State Food and Drug Administration in June this year.

In 2017, Wanbangde Pharmaceutical's Huperzine A products achieved sales revenue of 10.757 million yuan, accounting for 2.37% of the company's total revenue, bringing profits of 3.413 million yuan to the company and paying taxes of 2.194 million yuan.

On November 18, 2018, an expert seminar on clinical positioning of Huperzine A injection was held in Beijing. Wanbond Pharmaceutical hopes to sort out a suitable clinical positioning through the seminar, so as to carry out subsequent post-marketing evaluation and expand new indications. The scientific research achievements of this Chinese original drug with complete intellectual property rights have been carried forward. At the same time, it will further enhance the independent innovation ability of enterprises and promote the industrialization of scientific and technological achievements.

(News source: Wenling Daily)